Semaglutide
vs
Tirzepatide
Side-by-side comparison of mechanism, research, dosing, side effects, and pricing.
Semaglutide
FDA-approved GLP-1 agonist. The most-studied weight management peptide.
Tirzepatide
Dual receptor agonist. Outperforms semaglutide in head-to-head trials.
Research base
200+ clinical trials. Strongest evidence base for weight research peptides. Works as researched.
FDA approved. Phase 3 trials show superior metabolic effects vs single-receptor agonists.
How they work
GLP-1 receptor agonist. Decreases appetite, slows gastric emptying, improves insulin sensitivity.
Activates both GLP-1 and GIP receptors. Dual-pathway stimulation.
Protocols compared
What to expect
Common: nausea (30%), GI adjustment. Usually resolve over time.
2-4 weeks for appetite suppression, 12+ weeks for significant changes
Common: GI adjustment. Well-tolerated overall.
Effects within 2-4 weeks
Price comparison
The honest verdict
Pick Semaglutide if: Strong standalone evidence. Most clinical trials test it alone.
Pick Tirzepatide if: Highly effective alone. Dual-agonist mechanism is its key feature.
Why not both? Some researchers run them together. Check our Interaction Matrix to see if these compounds synergize or work independently.
